Regulus Therapeutics Inc (NASDAQ:RGLS) shares traded -1.63% lower at $7.85 on Wall Street last session.
RGLS stock price is now 303.66% away from the 50-day moving average and 383.98% away from the 200-day moving average. The market capitalization of the company currently stands at $520.01M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $3 to $6, Wells Fargo Upgraded its rating from Equal Weight to Overweight for Regulus Therapeutics Inc (NASDAQ: RGLS). On August 02, 2024, Oppenheimer recently initiated its ‘Outperform’ rating on the stock quoting a target price of $7, while ‘Leerink Partners’ rates the stock as ‘Outperform’
In other news, Hagan Joseph P, Chief Executive Officer bought 50,000 shares of the company’s stock on Jan 30 ’25. The stock was bought for $54,260 at an average price of $1.09. Upon completion of the transaction, the Chief Executive Officer now directly owns 260,808 shares in the company, valued at $2.05 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 30 ’25, Director BALTIMORE DAVID bought 19,610 shares of the business’s stock. A total of $20,787 was incurred on buying the stock at an average price of $1.06. This leaves the insider owning 22,169 shares of the company worth $0.17 million. A total of 19.71% of the company’s stock is owned by insiders.
During the past 12 months, Regulus Therapeutics Inc has had a low of $0.83 and a high of $8.20. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 10.52, and a quick ratio of 10.52. The fifty day moving average price for RGLS is $1.9448 and a two-hundred day moving average price translates $1.62205 for the stock.
The latest earnings results from Regulus Therapeutics Inc (NASDAQ: RGLS) was released for 2024-12-31. The company reported revenue of $13.74 million for the quarter, compared to $8.3 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 65.59 percent.
